GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » cbdMD Inc (AMEX:YCBDPA.PFD) » Definitions » Debt-to-Revenue

cbdMD (YCBDPA.PFD) Debt-to-Revenue : 0.08 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is cbdMD Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

cbdMD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1.03 Mil. cbdMD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.59 Mil. cbdMD's annualized Revenue for the quarter that ended in Dec. 2024 was $20.45 Mil. cbdMD's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.08.


cbdMD Debt-to-Revenue Historical Data

The historical data trend for cbdMD's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

cbdMD Debt-to-Revenue Chart

cbdMD Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.14 0.14 0.15 0.07

cbdMD Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.33 0.20 0.07 0.08

Competitive Comparison of cbdMD's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


cbdMD's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, cbdMD's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where cbdMD's Debt-to-Revenue falls into.


;
;

cbdMD Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

cbdMD's Debt-to-Revenue for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.27 + 0) / 19.482
=0.07

cbdMD's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.034 + 0.592) / 20.452
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


cbdMD Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of cbdMD's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


cbdMD Business Description

Traded in Other Exchanges
Address
2101 Westinghouse Boulevard, Suite A, Charlotte, NC, USA, 28273
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

cbdMD Headlines

From GuruFocus

Q1 2020 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 05-16-2024

Q2 2023 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2021 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q3 2023 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2022 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2020 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024